Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation - sprookjes - yvandenbroek - TriplyDB

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

http://www.wikidata.org/entity/Q34272562

about

Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation.Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major.Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study.Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation

P2860

Q30240070-0FF0D0D3-6776-4771-9DF6-DF66911003D5 Q38783289-33645CB3-78E7-432A-9441-A762CCBFE06F Q39422416-970679FA-E975-4BEE-B5A2-BEDA182051BA Q47203177-67148539-950F-4501-ABC2-7DC1198F2E40 Q57515058-F3E82B9F-1EE9-433E-B6FF-6C69913673AC

P2860

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

http://www.wikidata.org/entity/Q34272562

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phase IV open-label study of t ...... neic stem cell transplantation

@ast

Phase IV open-label study of t ...... neic stem cell transplantation

@en

Phase IV open-label study of t ...... neic stem cell transplantation

@nl

type

label

Phase IV open-label study of t ...... neic stem cell transplantation

@ast

Phase IV open-label study of t ...... neic stem cell transplantation

@en

Phase IV open-label study of t ...... neic stem cell transplantation

@nl

prefLabel

Phase IV open-label study of t ...... neic stem cell transplantation

@ast

Phase IV open-label study of t ...... neic stem cell transplantation

@en

Phase IV open-label study of t ...... neic stem cell transplantation

@nl

P1433

Q34272562-55309618-F1B0-41FA-AAF8-87D9FAB30663

P1476

Q34272562-6BDD115B-E7C6-4CBD-A3F0-C49958A6C42D

P2093

Q34272562-00ACCCBF-10C3-41CF-9A8F-235B44E65B9A

Q34272562-0AE3D515-FC05-4155-ACED-9731387948AD

Q34272562-0C783034-F26C-47F1-AC25-B3C8C3FF5815

Q34272562-19AB9328-CE79-4554-AE7B-9CE54E7A141A

Q34272562-2F5281C8-2D9C-4D99-AD16-598D15B67762

Q34272562-4A6CC9B9-EA6C-4C2C-8C2D-A5DFA61F5474

Q34272562-921981A4-1695-4187-BD60-70EF79F9BF5A

Q34272562-93D57EA4-9984-43CD-9CBF-E992D543AAF3

Q34272562-A275337E-1DF7-4583-BC34-5C9E608D7317

Q34272562-AB2E8F50-B64F-4290-AE6E-D50B8025F6FB

P2860

Q34272562-1C344D59-83C5-4F51-BE1A-293E8ED73585

Q34272562-2027E2A1-4006-4C7F-AA40-BDF41E692035

Q34272562-2E58C194-DCEA-440B-8B65-6F4D6FBF848A

Q34272562-464E92AF-CA26-40CE-9A2C-BCE3F60F28FB

Q34272562-511379A8-24AA-409F-A97E-493E2EF0109B

Q34272562-5B3FA35E-E976-4D58-82E4-174CA9FA3CAA

Q34272562-6EBCD848-93C8-408C-A960-988F84738C48

Q34272562-7584BC91-3472-4DDE-8231-AA50828788D1

Q34272562-8DF4FB2E-F002-4B10-B04E-7D34649E68D5

Q34272562-A59B8BBE-2980-455C-A19F-C584A14B64DB

P304

Q34272562-E23417D1-6B19-4D61-B1A4-D379BE659F57

P31

Q34272562-176420A2-7C1B-4863-BA32-0D82D724FAF0

P356

Q34272562-CC5BED94-6902-4869-8CBB-C561E4DD83FE

P433

Q34272562-61597C9E-30B9-4599-8B63-AB490A140112

P478

Q34272562-9146FEA8-F33A-4AA5-A22E-903CE4F8E794

P577

Q34272562-112478E4-A05E-4C7D-A4BD-D9AA3B873D92

P5875

Q34272562-D166DDC3-8376-421B-AEE9-F9EA2F736BA4

P698

Q34272562-B5E6BC40-702D-4288-AB9A-B4993481B7F8

P932

Q34272562-8593604D-9B26-4479-AC4D-331C0B6D5561

P356

HAEMATOL.2014.105908

P1433

P1476

Phase IV open-label study of t ...... neic stem cell transplantation

@en

P2093

Antonia Sampol

http://www.w3.org/2001/XMLSchema#string

Carlos Solano

http://www.w3.org/2001/XMLSchema#string

Carlos Vallejo

http://www.w3.org/2001/XMLSchema#string

David Valcárcel

http://www.w3.org/2001/XMLSchema#string

Dolores Hernández

http://www.w3.org/2001/XMLSchema#string

Isidro Jarque

http://www.w3.org/2001/XMLSchema#string

Javier López

http://www.w3.org/2001/XMLSchema#string

Lourdes Vázquez

http://www.w3.org/2001/XMLSchema#string

Montserrat Batlle

http://www.w3.org/2001/XMLSchema#string

Montserrat Rovira

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of patients with hereditary haemochromatosis by magnetic resonance imaging and spectroscopic relaxation time measurements.

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation

Does iron overload really matter in stem cell transplantation?

Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content.

Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.

Iron overload and allogeneic hematopoietic stem-cell transplantation.

The management of iron overload in allogeneic hematopoietic stem cell transplant (alloHSCT) recipients: where do we stand?

Iron overload in bone marrow transplant recipients.

MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation.

Early clinical impact of iron overload in stem cell transplantation. A prospective study.

P304

1632-1637

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2014.105908

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263744938

http://www.w3.org/2001/XMLSchema#string

P698

24997153

http://www.w3.org/2001/XMLSchema#string

P932

4181261

http://www.w3.org/2001/XMLSchema#string